European Medicines Agency

London 29 May 2006
Doc. Ref.: EMEA/186645/2006

PUBLIC STATEMENT ON
UPRIMA
(apomorphine hydrochloride**)**

NON-RENEWAL OF THE MARKETING AUTHORISATION IN THE EUROPEAN UNION

On 28 May 2001 the European Commission granted a Marketing Authorisation for the whole European Union to Abbott Laboratories Limited, for Uprima (apomorphine hydrochloride), indicated for the treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.

Uprima was marketed in Ireland, UK, Spain, France, Sweden and Norway. The Marketing Authorisation Holder did not apply to renew the Marketing Authorisation for commercial reasons and consequently on 28 May 2006 the 5-year Marketing Authorisation for Uprima expired.

Following the expiring of the Community Marketing Authorisation the European Public Assessment Report for Uprima has been removed from the EMEA website.

Noël Wathion
Head of Unit
Post-Authorisation Evaluation of Medicinal Products for Human use

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68
E-mail: mail@emea.eu.int http://www.emea.eu.int